Paper Details

  1. Home
  2. Paper Details

Selexipag for the Treatment of Pulmonary Arterial Hypertension.

Author: , AdzerikhoIgor, ChannickRichard, ChinKelly M, Di ScalaLilla, FreyAline, GaineSean, GalièNazzareno, GhofraniHossein-Ardeschir, HoeperMarius M, LangIrene M, LiuJinming, McLaughlinVallerie V, MoiseevaOlga, PreissRalph, RubinLewis J, SimonneauGérald, SitbonOlivier, TapsonVictor, ZengXiaofeng

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Selexipag was found to be effective in reducing the risk of death or a complication related to pulmonary arterial hypertension in patients with pulmonary arterial hypertension.
Paper Details　
Original Abstract of the Article :
BACKGROUND: In a phase 2 trial, selexipag, an oral selective IP prostacyclin-receptor agonist, was shown to be beneficial in the treatment of pulmonary arterial hypertension. METHODS: In this event-driven, phase 3, randomized, double-blind, placebo-controlled trial, we randomly assigned 1156 patien...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJMoa1503184

データ提供：米国国立医学図書館（NLM）

Selexipag: A New Weapon in the Fight Against Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) is a serious condition that can be as challenging to treat as crossing a vast desert. This study investigates the effectiveness of selexipag, a new oral medication, in the treatment of PAH. Selexipag works by activating the IP prostacyclin receptor, a crucial player in regulating blood pressure and blood vessel function.

The study, a large-scale randomized controlled trial, found that selexipag significantly reduced the risk of death or PAH-related complications compared to placebo. The study also found that selexipag was well-tolerated, with the most common side effects being consistent with known side effects of prostacyclin, such as headache and diarrhea.

A Promising New Treatment for PAH

This study offers a promising new treatment option for patients with PAH. Selexipag demonstrates the potential of targeting the IP prostacyclin receptor to improve outcomes in patients with this challenging condition. This research highlights the importance of developing new therapies that target specific pathways to improve treatment effectiveness and patient outcomes.

Navigating the Desert of PAH

This research underscores the importance of continued research and development of new treatments for PAH. Selexipag represents a promising new therapy, but further research is needed to fully understand its long-term effectiveness and safety. This research emphasizes the importance of a multi-pronged approach to treating complex conditions like PAH, combining medication, lifestyle modifications, and supportive care.

Dr. Camel's Conclusion

This study on selexipag provides a promising insight into the treatment of pulmonary arterial hypertension (PAH). Selexipag's effectiveness in reducing the risk of death or PAH-related complications highlights the potential of targeting the IP prostacyclin receptor to improve outcomes in patients with this challenging condition. This research underscores the importance of continued research and development of new therapies for PAH, offering hope for those navigating the complexities of this disease.

Date :
  1. Date Completed 2015-12-31
  2. Date Revised 2022-04-10
Further Info :

Pubmed ID

26699168

DOI: Digital Object Identifier

10.1056/NEJMoa1503184

Related Literature

Article Analysis
・Side Effects of selexipag
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.